Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Chong Kun Dang

Status and phase: Completed; Phase 3

Conditions: Dyslipidemia Patients With Hypertension

Treatments: Drug: D013, placebo of D326, placebo of D337; Drug: D013, D326, D337; Drug: placebo of D013, D326, D337

Study type: Interventional

Funder types: Industry

Identifiers

NCT04312698

A83_03DL/HT1903

Details and patient eligibility

About

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Enrollment: 100 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subjects are diagnosed with Dyslipidemia Patients with Hypertension or are being administered anti-hypertension and anti-hypertension drugs after diagnosis.
2. Subjects who agreed to participate in this clinical trial voluntarily.

Exclusion criteria

1. Subjects who were satisfied specific blood pressure levels that measured at screening period.
2. Subjects who were satisfied specific lipid levels that measured at screening period.
3. Subjects who cannot participate in a clinical trial based on the PI's judgment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 3 patient groups, including a placebo group

Experimental Group 1

Experimental group

Treatment:

Drug: D013, D326, D337

Comparator Group 1

Placebo Comparator group

Treatment:

Drug: placebo of D013, D326, D337

Comparator Group 2

Placebo Comparator group

Treatment:

Drug: D013, placebo of D326, placebo of D337